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The Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1 are both essential for lytic EBV replication.
BZLF1 is a transcriptional activator which binds directly to the lytic origin of replication (oriLyt) and plays
a critical role in the disruption of viral latency. The BMRF1 protein is required for viral polymerase proces-
sivity. Here we demonstrate that the BMRF1 gene product functions as a transcriptional activator and has
direct (as well as indirect) interactions with the BZLF1 gene product. The BMRF1 gene product activates an
essential oriLyt promoter, BHLF1, but does not activate two other early EBV promoters (BMRF1 and BHRF1).
Direct interaction between the BMRF1 and BZLF1 gene products requires the first 45 amino acids of BMRF1
and the bZip domain of BZLF1. The effect of the BZLF1-BMRF1 interaction on early EBV transcription is
complex and is promoter specific. The oriLyt BHLF1 promoter is activated by either the BZLF1 or BMRF1
gene product alone and is further activated by the combination of the BZLF1 and BMRF1 gene products.
Enhanced activation of BHLF1 transcription by the BMRF1-BZLF1 combination does not require direct
interaction between these proteins. In contrast, BZLF1-induced activation of the BMRF1 promoter is inhibited
in the presence of the BMRF1 gene product. A point mutation in the BZLF1 protein (amino acid 200), which
prevents in vitro interaction with the BMRF1 protein but which does not reduce BZLF1 transactivator
function, allows the BZLF1 protein to activate the BMRF1 promoter equally well in the presence or absence
of the BMRF1 gene product. Therefore, direct interaction between the BZLF1 and BMRF1 proteins may inhibit
BZLF1-induced transcription of the BMRF1 promoter. BZLF1 mutated at amino acid 200 is as efficient as
wild-type BZLF1 in promoting replication of an oriLyt plasmid. However, this mutation reduces the ability of
BZLF1 to induce lytic replication of the endogenous viral genome in D98/HE-R-1 cells. Our results indicate
that functional and physical interactions between the BMRF1 and BZLF1 proteins may modulate the efficiency
of lytic EBV infection. The BMRF1 gene product clearly has a transcriptional, as well as replicative, role during
lytic EBV infection.
Epstein-Barr virus (EBV) is a human herpesvirus which is
closely associated with some human malignancies, including
Burkitt’s lymphoma and nasopharyngeal carcinoma (45, 75). In
the latent form of EBV infection, the virus replicates as an
episome using the oriP origin of replication in conjunction with
the viral protein EBNA-1 (37). With the onset of lytic infec-
tion, the virus converts to a linear form and uses a different
origin of replication, oriLyt (32). Lytic EBV replication re-
quires the gene products of six viral genes: BALF5 (the cata-
lytic component of the viral polymerase), BMRF1 (the poly-
merase processivity factor), BALF2 (single-stranded DNA
binding protein), BSLF1 (primase), BBLF4 (helicase), and
BBLF2/3 (helicase-primase-associated protein) (20, 21). In ad-
dition, the immediate-early gene product BZLF1 plays an es-
sential role in lytic EBV replication (21, 54).
Overexpression of BZLF1 in EBV-infected cells is sufficient
to initiate conversion of latent infection into productive infec-
tion (8, 12, 52, 60). The BZLF1 protein, a member of the bZip
family, is a transcriptional activator which binds directly as a
homodimer to Ap1-like BZLF1-responsive elements (ZREs)
(4, 9, 19, 23, 43, 65). The BZLF1 protein activates expression
of early viral proteins, including essential replicative proteins
(3, 5, 7, 13, 33, 35, 36, 50).
However, recent studies suggest that in addition to its tran-
scriptional function, BZLF1 plays a direct role in oriLyt rep-
lication. The minimal oriLyt contains the transcriptional con-
trol regions for two EBV early genes, BHLF1 and BHRF1
(32). There are seven BZLF1 binding motifs (ZREs) within
oriLyt, and mutation of these sites completely abolishes oriLyt
replication (54). Although these binding sites are important for
transcriptional activation of the BHLF1 and BHRF1 promot-
ers, BZLF1 binding to oriLyt appears to be required for oriLyt
replication in a manner independent of its transcriptional ac-
tivator role. Replacement of the oriLyt ZREs with alternative
transcriptional activator binding motifs does not rescue oriLyt
replication, although transcription can be restored (54). Fur-
thermore, even when the six essential viral replicative proteins
are expressed under the control of strong heterologous pro-
moters, BZLF1 is still required for oriLyt-mediated replication
(21). Although BZLF1 is essential for oriLyt replication, the
mechanism(s) by which BZLF1 promotes replication are not
fully defined and seem to be separable from transcriptional
activation. Interestingly, the BMRF1 and BZLF1 gene prod-
ucts have been shown to colocalize within intranuclear viral
replication compartments (61).
In this report, we demonstrate that the BMRF1 gene prod-* Corresponding author. Phone: (919) 966-1248. Fax: (919) 966-3015.
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uct, in addition to its role as the polymerase processivity factor
(6, 10, 11, 14, 38, 39, 42, 62–64), activates expression of an
essential oriLyt promoter, BHLF1. We also find that the
BMRF1 gene product interacts directly with the BZLF1 gene
product in vitro as well as in vivo. The BMRF1-BZLF1 inter-
action is mediated through the first 45 amino acids of BMRF1
and the bZip domain of BZLF1 and produces promoter-spe-
cific effects. The early BHLF1 promoter is activated by either
the BMRF1 or BZLF1 gene products alone and is further
activated by the combination of the BZLF1 and BMRF1 gene
products. However, the BMRF1 gene product inhibits BZLF1-
induced activation of its own promoter.
A BZLF1 protein mutated at amino acid 200 cannot interact
in vitro with the BMRF1 gene product. This mutant BZLF1
protein is similar to wild-type BZLF1 as a transcriptional ac-
tivator and has equivalent function in plasmid-based oriLyt
replication assays. Nevertheless, mutation of amino acid 200
reduces the ability of BZLF1 to activate lytic infection of the
endogenous viral genome in D98/HE-R-1 cells. The direct and
indirect interactions between BZLF1 and BMRF1 may there-
fore modulate the efficiency of lytic EBV replication.
MATERIALS AND METHODS
Cell lines. HeLa is a cervical epithelial cell line. The latently infected D98/
HE-R-1 cell line was formed by fusion of a HeLa subclone (D98) with the
EBV-positive Burkitt’s lymphoma P3HR-1 (27). Epithelial cells were maintained
in Dulbecco modified Eagle medium H supplemented with 10% fetal calf serum.
The B95-8 cell line (an EBV-infected marmoset B-cell line) and the Akata cell
line (an EBV-positive human Burkitt lymphoma line) (59) were maintained in
RPMI 1640 medium with 10% fetal calf serum.
Plasmids. The construction of the BZLF1 expression plasmid pCMV-Z has
been described previously (50). pCMV-Z contains the BZLF1 cDNA (a gift from
Paul Farrell) in the pGEM2-based vector pHD1013 (a gift from E. S. Huang)
such that the BZLF1 immediate-early gene is under the control of the strong
cytomegalovirus immediate-early promoter. The BMRF1 expression plasmid
contains the 1,341-bp BclI-BglII fragment (from the BamHIM fragment of EBV)
(1) subcloned in the BamHI and BglII sites of the pSG5 vector (Stratagene) such
that BMRF1 gene expression is driven by the simian virus 40 (SV40) early
promoter. The BMRF1 in vitro translation plasmid contains the identical BclI-
BglII fragment inserted into the pBS SK1 phagemid vector (Stratagene). The
promoter plasmids BMRF1-CAT and BHRF1-CAT have been described previ-
ously (31, 50) and contain the early EBV promoters BMRF1 and BHRF1 linked
to the chloramphenicol acetyltransferase (CAT) gene in the Bluescript SK1
phagemid vector (Stratagene). The BHLF1-CAT plasmid contains the early
BHLF1 promoter (amino acids 21031 to 1165 relative to the mRNA start site)
linked to CAT in the Bluescript SK1 vector. The plasmids for in vitro translation
of wild-type BZLF1 protein and the double point mutants of the BZLF1 dimer-
ization domain (a gift from Erik Flemington and Sam Speck) have been de-
scribed elsewhere (24, 31). Single point mutations of the BZLF1 bZip domain
were made with the CLONTECH transformer site-directed mutagenesis kit
according to the manufacturer’s instructions. All point mutants were sequenced.
BZLF1D200 contains a tyrosine to glutamic acid mutation, and BZLF1D225
contains a leucine to glutamic acid mutation. The oriLytDKpn plasmid (used in
plasmid replication assays) was made by ligating the EBV SstII-HincII fragment
(EBV sequences 52,623 to 53,819) into the HincII site of the pBS1 plasmid
(Stratagene). The nonessential KpnI-KpnI fragment of oriLyt (EBV sequences
52,944 to 53,207) was subsequently deleted. The plasmid pRZSphHind contains
the HindIII-SpHI fragment (spanning the EBV sequences from 2235 to 1115
relative to the BZLF1 mRNA start site) inserted into the HincII site of the pBS1
plasmid (Stratagene). This plasmid was used to generate a riboprobe for RNase
protection assays.
Bacterial proteins. The construction of the glutathione S-transferase (GST)-Z
fusion protein has been previously described (31, 73). GST-Z contains the entire
BZLF1 open reading frame inserted in frame into the pGEX-3X vector (Phar-
macia) downstream of the GST protein. In-frame deletions of GST-Z were
constructed and named to reflect the deleted amino acids (see Fig. 3A). The
GST-BMRF1 protein contains the first 303 residues of BMRF1 cloned in frame
in the pGEX-3X vector, downstream of the GST protein. In-frame deletions of
GST-BMRF1 were also constructed and named to reflect the amino acids miss-
ing (see Fig. 2B).
DNA transfections. Plasmid DNA was purified by using a QIAGEN Maxi kit
as specified by the manufacturer. DNA was transfected by electroporation, using
10 mg of DNA and 107 cells per condition. Cells were shocked at 1,500 V with a
Zapper electroporation unit (Medical Electronics Shop, University of Wisconsin,
Madison, Wis.). Epithelial cells were harvested and suspended into RPMI 1640
medium before electroporation.
CAT assays. Cell extracts were prepared 48 h after transfection and incubated
at 378C with [14C]chloramphenicol in the presence of acetyl coenzyme A as
described previously (28). The percent acetylation of chloramphenicol was
quantitated by thin-layer chromatography followed by scintillation counting or
AMBIS scanning (AMBIS, Inc.).
EBV terminus analysis. To distinguish latent versus productive EBV infection,
Southern blot analysis was used to determine the state of the EBV termini (fused
versus unfused). Total cellular DNA was analyzed 3 days after transfection with
the BZLF1 expression plasmid by cutting it with the BamHI enzyme and probing
with a 32P-labelled riboprobe spanning the EBV sequences in the 1.9-kb XhoI
fragment. As previously described (51), this probe can be used to determine the
relative amount of EBV DNA containing fused versus unfused viral termini.
Unfused termini are only observed in the linear form of the virus and are
diagnostic of lytic infection.
oriLyt plasmid replication assays. oriLyt plasmid replication assays were per-
formed as previously described (54, 55). The oriLytDKpn plasmid was trans-
fected into D98/HE-R-1 cells with either pHD1013 vector DNA, the wild-type
BZLF1 expression plasmid, or the mutant BZLF1 expression plasmid. Total
cellular DNA was harvested 3 days after transfection, cut with the BamHI and
DpnI restriction enzymes, separated on an agarose gel, and analyzed by the
Southern blot technique using a 32P-labelled single-stranded RNA probe span-
ning oriLyt. The efficiency of replication was determined by quantitating the
amount of the replicated (Dpn-resistant) band in each condition, with the input
DNA band serving as a control for transfection efficiency.
Coimmunoprecipitation and immunoblot analysis. Coimmunoprecipitation
experiments were performed 3 days after induction of B95-8 cells with TPA
(12-O-tetradecanoylphorbol-13-acetate) and sodium butyrate. Cells were rinsed
with cold phosphate-buffered saline (PBS), pelleted, frozen in dry ice, thawed,
and resuspended in 0.4 ml of lysis buffer (50 mM Tris, 150 mM NaCl, 0.5 mM
EDTA, 0.5% Nonidet P-40 [NP-40] [pH 8.0]) supplemented with the protease
inhibitors 1 mM phenylmethylsulfonyl fluoride and 1 mM pepstatin (Boehringer-
Mannheim). The cell lysate was then sonicated six times and pelleted again, and
equal amounts of protein supernatant (approximately 100 mg) were incubated
overnight at 48C with 10 ml of either a BMRF1-specific monoclonal antibody
(previously known as R3 [49]; Capricorn) or an Rb-specific monoclonal antibody
(Santa Cruz Biotechnology). Extracts were then immunoprecipitated with pro-
tein A-Sepharose 4B beads (Sigma) and washed five times at 48C in buffer
containing 20 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid
(HEPES; pH 7.7), 75 mM KCl, 0.1 mM EDTA, 25 mM MgCl2, 10 mM dithio-
threitol, and 0.15% NP-40. The immunoprecipitated proteins were separated on
a sodium dodecyl sulfate (SDS)–8% gel, transferred to nitrocellulose paper, and
analyzed by immunoblot analysis using the BZLF1-specific antibody BZ.1 (di-
rected against the dimerization domain) (71). Immunoblot analysis was per-
formed in PBS with 5% powdered milk, using a 1:10 dilution of BZ.1 monoclonal
antibody, followed by washing three times in room temperature with 3% pow-
dered milk–PBS and then addition of the secondary antibody (1:2,000 dilution of
goat anti-mouse kappa chain horseradish peroxidase-conjugated serum [South-
ern Biotechnology Associates]). Immunoblotting was done by using enhanced
chemiluminescence performed as recommended by the manufacturer (Amer-
sham Life Sciences).
GST-fusion protein affinity chromatography. The interaction of the 35S-la-
belled in vitro-translated BZLF1 and BMRF1 proteins with the GST-BMRF1
and GST-BZLF1 fusion proteins was analyzed by affinity chromatography as
previously described (57, 66). Bacterial cultures (50 ml) containing the various
pGEX vectors were induced with 0.4 mM isopropyl-b-thiogalactopyranoside
(IPTG) and then pelleted and resuspended in 5 ml of PBS, sonicated, and
cleared of bacterial debris by centrifugation at 12,000 3 g. For each condition,
100 ml of lysate was then incubated in 1 ml of PBS for 20 min at room temper-
ature with 10 ml of 50% glutathione-agarose beads (Sigma) and the GST proteins
were purified by three cycles of centrifugation and washing in 1-ml aliquots of
PBS, followed by one wash in 1-ml aliquots of buffer containing 20 mm HEPES
(pH 7.7), 25 mM NaCl, 0.1 mM EDTA, 25 mMMgCl2, 1 mM dithiothreitol, and
0.15% NP-40. The purified GST protein was then resuspended in 1 ml of the final
wash buffer with 15 ml of 35S-labelled, in vitro-translated protein for 1 h at room
temperature. Bead complexes were washed five times in the above buffer, cen-
trifuged, resuspended in Laemmli sample buffer, and then analyzed by electro-
phoresis on SDS–8% polyacrylamide gels, followed by autoradiography. In par-
allel experiments, the purified GST fusion proteins were analyzed by
electrophoresis on SDS–8% polyacrylamide gels to show that each of these
proteins was intact and present in equivalent amounts.
Electromobility shift assays. Electromobility shift assays were performed as
previously described (26). Whole cell extracts were prepared by washing the cells
twice with ice-cold PBS and then resuspending the cell pellet in 0.4 ml of lysis
buffer (50 mM Tris [pH 7.9], 150 mM NaCl, 0.5% NP-40 [pH 8.0], 0.5 mM
EDTA, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and 1 mM of
pepstatin). The cell lysate was then sonicated six times and pelleted again. Equal
amounts of protein supernatant (approximately 10 mg) were incubated with
either 10,000 cpm of a 32P-end-labelled probe containing the four BZLF1 bind-
ing motifs from the BHLF1 promoter (the SacII-KpnI fragment from EBV
sequences [1] 52,623 to 52,944) or a 32P-end-labelled oligonucleotide probe
(59GATCATGTGCAAGCTATGTGCAATG39 and 59GATCCATTGCACAT
AGCTTGCACAT39) containing two consensus ZRE sites. Binding reactions
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were carried out at room temperature for 15 min (prior to adding the labelled
probe) in a buffer consisting of 50 mM Tris (pH 7.9), 250 mM NaCl, 5 mM
MgCl2, 2.5 mM EDTA, and 5 mM dithiothreitol. Poly(dI-dC)-poly(dI-dC) (4 mg)
was added as a nonspecific competitor DNA. After addition of the labelled
probe, the reaction was incubated an additional 15 min at room temperature,
loaded onto a 4% polyacrylamide gel–1% Tris glycine gel, and run in 0.53 Tris
glycine buffer (0.25 M Tris, 0.19 M glycine) at room temperature. The gel was
dried and subjected to autoradiography.
RNase protection assays. Total cellular RNA was isolated by using the Trizol
reagent (GIBCO-BRL) 24 h after transfection of D98/HE-R-1 cells with the
pHD1013 vector or the wild-type or mutant BZLF1 expression vectors or 4 h
after treatment of Akata cells with TPA (30 ng/ml). RNase protection was
performed by using the RNase protection assay system (Promega) as described
by the manufacturer. The plasmid pRZSphHind was cut with DraI (position234
relative to the BZLF1 mRNA start site) and transcribed with T3 RNA polymer-
ase in the presence of 32P-labelled UTP to yield a 156-bp antisense riboprobe
spanning the Zp initiation site. Fifteen micrograms of total RNA was hybridized
with 20,000 cpm of riboprobe at 508C for 16 h and then digested with 3 U of
RNase I at room temperature for 1 h. Samples were denatured and fragments
were resolved by electrophoresis through an 8 M urea–polyacrylamide gel. Hy-
bridization to Zp- and Rp-initiated transcripts yields protected species of 115 and
148 bp, respectively. The transfected Z vector yields a protected fragment of 80
bp.
RESULTS
The BMRF1 gene product specifically activates the oriLyt
promoter BHLF1. In addition to its role as a replicative pro-
tein, the BMRF1 gene product was reported by one group to
activate the SV40 early promoter (47). However, two other
groups observed no BMRF1 transactivator function (6, 67),
and no EBV promoter has ever been shown to be activated by
the BMRF1 gene product. To examine the potential transcrip-
tional role of the BMRF1 protein during lytic replication,
cotransfection studies were performed in HeLa cells, using
reporter gene constructs driven by three different early EBV
promoters: the BMRF1 promoter, the BHRF1 promoter, and
the BHLF1 promoter. The BMRF1 promoter drives expres-
sion of the BMRF1 gene product, whereas the BHRF1 and
BHLF1 promoters are the two promoters contained within
oriLyt. Each of these promoters has been previously shown to
be directly bound (and activated) by the BZLF1 gene product
(4, 50, 54).
As shown in Fig. 1, the BMRF1 gene product in HeLa cells
had no significant effect on the constitutive activity of its own
promoter (BMRF1) or that of the BHRF1 promoter. How-
ever, the BMRF1 gene product produced a 20-fold activation
in the constitutive expression of the BHLF1 promoter. Similar
results were obtained in an EBV-negative B-cell line (data not
shown). Thus, in addition to its direct replicative function, the
BMRF1 gene product can activate a promoter (BHLF1) which
has previously been shown to be an essential element of oriLyt
(55).
The BZLF1 protein interacts directly with the BMRF1 gene
product through the BZLF1 bZip dimerization domain. The
previously reported colocalization of the BMRF1 and BZLF1
proteins within intranuclear viral replication compartments
(61) raised the possibility that these proteins may interact
directly. To confirm that the BZLF1 and BMRF1 proteins
directly interact and to map the domains in the BZLF1 and
BMRF1 proteins required for direct interaction, we performed
in vitro affinity chromatography assays with GST fusion pro-
teins (66). The BZLF1 and BMRF1 proteins (in vitro trans-
lated and labelled with 35S) were both retained by the GST-Z
protein (containing the entire 245-amino-acid BZLF1 open
reading frame fused in frame to GST) (Fig. 2A) but not by the
control GST protein alone. In contrast, the catalytic compo-
nent of the viral polymerase (BALF5) did not interact directly
with GST-Z.
In-frame deletions of the BMRF1 in vitro translation vector
and the GST-BMRF1 fusion protein were constructed to map
the domain(s) of BMRF1 required for interaction with BZLF1
(Fig. 2B). The results of these experiments indicate that inter-
action between the BMRF1 and BZLF1 gene products is me-
diated through the amino-terminal half of BMRF1 and re-
quires the first 45 amino acids of BMRF1 (Fig. 2C to E). It is
clear that the BMRF1-BZLF1 interaction does not require
BMRF1 DNA binding function, since a mutant form of
BMRF1 unable to bind DNA (BMRF1D124-217) still interacts
with BZLF1. Furthermore, a BMRF1 mutant missing the first
45 amino acids is unable to interact with BZLF1 in vitro,
although this mutant can bind DNA efficiently in vitro (17a).
Thus, the region of BMRF1 required for interaction with Z
appears to be separable from its DNA binding domain. In
contrast, the polymerase processivity function of BMRF1
clearly requires its DNA binding function (39).
To map the domain(s) of BZLF1 required for interaction
with BMRF1, we created a series of mutations within the
GST-Z and in vitro-translated BZLF1 proteins (Fig. 3A) and
analyzed the ability of such mutants to homodimerize and
interact with BMRF1. Preliminary mapping indicated that the
bZip dimerization domain of BZLF1 is sufficient for interac-
tion with BMRF1 (Fig. 3B). In vitro-translated proteins, each
containing two point mutations within the BZLF1 dimerization
domain (gifts from Erik Flemington), were then tested for the
ability to interact with the GST-BMRF1 fusion protein (Fig.
3C). A BZLF1 protein containing double point mutations
within amino acids 200 and 225 could homodimerize (although
less efficiently than wild-type BZLF1) but no longer interacted
efficiently with BMRF1. A BZLF1 protein containing point
mutations within amino acids 197 and 200 also shared this
phenotype but was not further studied since this particular
mutant has previously been shown to bind poorly to ZREs
(56).
We next constructed single point mutations in amino acids
FIG. 1. The BMRF1 gene product activates the BHLF1 oriLyt promoter.
Five micrograms of the BMRF1-CAT reporter construct (containing the early
EBV BMRF1 promoter), the BHRF1-CAT reporter construct (containing the
BHRF1 early EBV promoter), or the BHLF1-CAT reporter construct (contain-
ing the early EBV BHLF1 promoter) was transfected into HeLa cells with either
5 mg of pSG5 vector DNA (Vector) or 5 mg of the BMRF1 expression vector
(BMRF1). The percent acetylation of 14C-labelled chloramphenicol in each
condition was measured as previously described (28). Results are expressed as
the amount of CAT activity induced by the BMRF1 expression vector relative to
the amount induced by the vector alone.
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200 and 225 and tested each of these mutants for the ability to
homodimerize and interact with BMRF1 (Fig. 3D). The
BZLF1D200 protein (containing a tyrosine to glutamic acid
switch at residue 200) could homodimerize as efficiently as the
wild-type BZLF1 but was unable to interact efficiently with
BMRF1 at room temperature. This mutant protein was thus
used in subsequent studies to examine the functional role(s) of
the BZLF1-BMRF1 direct interaction. The BZLF1 protein
mutated at amino acid 225 could still interact with BMRF1
although with slightly reduced affinity.
The BZLF1 and BMRF1 proteins can be coimmunoprecipi-
tated in vivo. Coimmunoprecipitation studies were performed
to determine if the BZLF1 and BMRF1 gene products can
interact in vivo in EBV-infected cells. EBV-infected marmoset
B cells (B95-8) were treated for 48 h with TPA and sodium
butyrate as previously described (44, 74) to induce lytic EBV
infection. Cell extracts were immunoprecipitated with mono-
clonal antibodies directed against the BZLF1, BMRF1, or the
retinoblastoma (Rb) protein. The immunoprecipitated pro-
teins were then probed by immunoblot using the BZLF1-spe-
cific antibody.
As expected, in B95-8 cells, BZLF1 was immunoprecipitated
by the BZLF1-specific antibody and not immunoprecipitated
by the Rb antibody (Fig. 4). A portion of BZLF1 (approxi-
mately one-quarter of the BZLF1 protein precipitated by the
BZLF1-specific antibody) was also immunoprecipitated with
the BMRF1-specific antibody in the productively infected
B95-8 cells (which express BMRF1 protein). BZLF1 protein
overexpressed in EBV-negative HeLa cells was not immuno-
precipitated by the BMRF1 antibody (Fig. 4), excluding the
possibility that this antibody nonspecifically cross-reacts with
BZLF1. These results suggest that the BZLF1 and BMRF1
proteins can interact directly in productively infected cells.
We were unable to show an interaction between the BZLF1
FIG. 2. The BZLF1 and BMRF1 proteins interact in vitro. (A) The entire BZLF1 open reading frame was inserted in frame into the pGEX-3X vector (Pharmacia)
downstream of the GST protein to create the GST-Z fusion protein. The BMRF1, viral polymerase (BALF5), and BZLF1 proteins were in vitro translated, 35S-labelled,
and tested for their ability to interact with the GST-Z protein (or the GST protein alone) using affinity chromatography assays (66). Lanes: 1 to 3, input 35S-labelled,
in vitro-translated BMRF1, viral polymerase (Pol), and BZLF1 proteins (Z); 4 to 6, retention of each protein by the GST protein; 7 to 9, retention of each protein by
the GST-Z fusion protein. The size of each full-length in vitro-translated protein is indicated by a labelled arrow. The direct load contains 3 ml of the in vitro-translated
proteins, whereas 10 ml of each in vitro-translated protein was used in the affinity chromatography assays. Approximately 30% of the labelled BMRF1 and BZLF1
proteins is retained by the GST-Z protein. (B through E) In-frame deletions of the BMRF1 protein (removing the amino acids indicated) (C and D) were 35S-labelled,
in vitro translated, and evaluated for the ability to interact with GST-Z in affinity chromatography assays as shown in panel A. GST-BMRF1 fusion proteins (containing
the first 303 amino acids of BMRF1 fused to GST or missing the amino acids indicated) were also constructed and evaluated for their ability to retain in vitro-translated,
35S-labelled BZLF1 protein (panel E). The results are summarized on the right side of panel B. The BMRF1 residues between 1 and 193 and between 238 to 302 have
been previously shown to be required for DNA binding (39).
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and BMRF1 proteins when the experiment was performed in
the reverse direction (using BZLF1 antibody to immunopre-
cipitate and BMRF1 antibody to probe the immunoblot) (data
not shown). However, this negative result is not unexpected,
since the BZLF1 antibody recognizes an epitope within the
bZip dimerization domain (71) which was found to be the
domain also required for interaction between the BZLF1 and
BMRF1 proteins. The epitope recognized by the BZ.1 anti-
body may thus be obscured by the interaction between the
BZLF1 and BMRF1 gene products.
The BMRF1 gene product interacts with BZLF1 to regulate
early EBV promoters in a promoter-specific fashion. The pre-
vious results suggested that the BMRF1 gene product, like
BZLF1, functions as a transcriptional activator and, further-
more, that these two proteins can directly interact. Given that
both of these proteins are expressed during lytic EBV infec-
tion, we next determined if the BMRF1-BZLF1 combination
produces synergistic (or antagonistic) effects on the activity of
early EBV promoters. We compared the effect of the BZLF1
gene product alone, the BMRF1 gene product alone, and the
combination of the two proteins together on three different
early EBV promoters (BMRF1, BHRF1, and BHLF1). Each
of these promoters is activated by the BZLF1 protein alone,
although (as shown in Fig. 1) only the BZLF1 promoter is
activated by the BMRF1 gene product alone.
As shown in Fig. 5A, cotransfection of BMRF1 and BZLF1
did not alter the expression of either gene product, as detected
by immunoblot. The effect of the BMRF1 gene product on
BZLF1-induced activation of early EBV promoters was found
to be complex and promoter specific. The BHRF1 promoter
was not activated by the BMRF1 gene product alone, and
cotransfection of BMRF1 protein did not alter the level of
FIG. 3. The bZip dimerization domain of BZLF1 is required for interaction
with the BMRF1 protein. In-frame deletions of the GST-Z protein or point
mutants of BZLF1 (derived from the in vitro-translation vector) were con-
structed (A). Constructs are named to reflect the amino acid(s) deleted or
mutated. Each mutant protein was tested for the ability to interact with the
BZLF1 and BMRF1 proteins with affinity chromatography assays (B, C, and D).
Results are summarized on the right of panel A. Approximately 30% of the total
labelled BZLF1 protein was retained by GST-BMRF1.
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BZLF1-induced activation (Fig. 5B). In the case of the
BMRF1 promoter, the BMRF1 gene product alone produced
no effect, but the presence of cotransfected BMRF1 protein
significantly inhibited the activation produced by BZLF1 alone
(Fig. 5C).
The BHLF1 promoter was consistently activated by either
the BMRF1 gene product alone or the BZLF1 gene product
alone (Fig. 5D). Furthermore, activation of the BHLF1 pro-
moter was consistently greater with the combination of the
BZLF1 and BMRF1 gene products than with either protein
alone. Thus, the BHLF1 promoter element, which overlaps a
known essential domain in oriLyt (55), is specifically activated
by the BMRF1 gene product alone and is further activated by
the combination of the BZLF1 and BMRF1 gene products
together.
BMRF1 decreases BZLF1 binding to ZREs. The BZLF1
protein binds to a specific Ap1-like motif present in most early
EBV promoters, including the BMRF1, BHLF1, and BHRF1
promoters. The BMRF1 protein has potent nonspecific DNA
binding activity but is not known to bind to a specific DNA
motif (39). To determine if the BMRF1 protein can alter
BZLF1 binding to DNA, the amount of specific BZLF1 bind-
ing to a synthetic 32P-labelled oligonucleotide probe containing
two ZREs was compared using protein extracts from cells
transfected with BZLF1 alone, BMRF1 alone, or a combina-
tion of the BZLF1 and BMRF1 gene products (Fig. 6). Under
our electromobility shift assay conditions, cells transfected with
BMRF1 alone did not have an observable protein binding to
the ZRE probe (presumably because BMRF1 binding activity
was completely inhibited by the unlabelled, nonspecific com-
petitor DNA). The extracts from cells transfected with the
BZLF1 protein alone, as expected, contained a binding protein
(BZLF1) which was specifically inhibited by the Ap1 binding
motif. In the presence of cotransfected BMRF1 protein,
BZLF1 binding to the ZRE probe was consistently decreased
(by an average of 75%). No new binding complex (as might be
expected if the BMRF1-BZLF1 heterodimer binds DNA) was
observed. Similar results were obtained using in vitro-trans-
lated BZLF1 and BMRF1 proteins (data not shown). A probe
containing the four ZRE sites in the BHLF1 promoter also
produced similar results (data not shown), indicating that de-
creased BZLF1 binding in the presence of BMRF1 is not
probe specific. As shown in Fig. 5A, the presence of the co-
transfected BMRF1 gene product did not alter the level of
transfected BZLF1 in these extracts.
These results are consistent with the hypothesis that the
BMRF1-BZLF1 complex is less efficient in binding to ZREs.
We cannot completely exclude the possibility that the BZLF1-
BMRF1 binding complex is too unstable to be seen under our
gel electrophoresis conditions or that the BZLF1-BMRF1
complex specifically binds to alternative DNA motifs. The very
potent nonspecific DNA binding ability of BMRF1 may make
the ZRE probe unavailable for specific BZLF1 binding in
these assays.
Direct interaction between the BZLF1 and BMRF1 proteins
in vitro correlates with the ability of the BMRF1 gene product
to inhibit its own transcription but is not required for syner-
gistic activation of the BHLF1 promoter. The previous results
indicate that the interactions between the BMRF1 and BZLF1
transcription factors produce complex, promoter-specific ef-
fects. It is likely that indirect, as well as possibly direct, inter-
actions between the BZLF1 and BMRF1 proteins contribute
to these effects. To determine what role, if any, the direct
interaction between the BZLF1 and BMRF1 proteins plays in
the transcriptional regulation of early EBV promoters, we ex-
amined whether mutation of BZLF1 amino acid 200 (a muta-
tion which prevents direct interaction with the BMRF1 protein
in vitro) alters the interactions between BZLF1 and BMRF1 in
vivo.
As shown in Fig. 7A, the mutant BZLF1D200 protein is not
intrinsically impaired as a transcriptional activator, although it
may be slightly less stable than wild-type BZLF1 in vivo (Fig.
7C). Interestingly, mutation of BZLF1 amino acid 200 was
found to alter the interaction between the BZLF1 and BMRF1
proteins in vivo in regard to regulation of the BMRF1 pro-
moter (Fig. 7A). Whereas the ability of wild-type BZLF1 to
activate BMRF1 transcription was consistently decreased by
the presence of the BMRF1 gene product (P , 0.5 in a two-
tailed t test), the ability of mutant BZLF1 protein to activate
BMRF1 transcription was not significantly inhibited by the
BMRF1 gene product. Thus, direct interaction between the
BZLF1 and BMRF1 proteins in vitro correlates with the ability
of the BMRF1 gene product to inhibit its own transcription in
vivo.
In the case of the BHLF1 promoter, which is maximally
activated by the combination of the BMRF1 and BZLF1 pro-
teins, the mutant BZLF1 protein, like wild-type BZLF1, could
also interact with the BMRF1 gene product to enhance
BHLF1 transcription (Fig. 7B). Therefore, the increased
BHLF1 promoter activity induced by the BMRF1-BZLF1
combination in vivo did not correlate with the ability of the
BZLF1 and BMRF1 proteins to interact in vitro. Since it has
previously been shown that BZLF1 can sometimes activate
transcription through a nonbinding mechanism (presumably
mediated through interactions between BZLF1 and other tran-
scription factors) (22), we also examined whether a nonbinding
mutant of BZLF1, Z311 (mutated at residue 185) (35), can
cooperate with the BMRF1 gene product to activate the
BHLF1 promoter. The Z311 mutant was unable to activate the
BHLF1 promoter efficiently by itself (Fig. 7b) and could not
cooperate with the BMRF1 gene product to activate BHLF1
transcription. Therefore, activation of the BHLF1 promoter by
the BMRF1-BZLF1 combination requires a BZLF1 DNA
FIG. 4. The BZLF1 and BMRF1 proteins can be coimmunoprecipitated in
vivo. The EBV-positive marmoset B-cell line, B95-8, was treated for 48 h with
TPA and sodium butyrate as previously described (44, 74) to induce lytic viral
infection. Cell extracts were prepared and immunoprecipitated with either a
BZLF1-specific monoclonal antibody (BZ.1), a BMRF1-specific monoclonal an-
tibody (Capricorn), or a monoclonal antibody directed against the cellular reti-
noblastoma tumor suppressor protein, Rb. The immunoprecipitated proteins
were separated by SDS-polyacrylamide gel electrophoresis, transferred to a ni-
trocellulose filter, and analyzed by immunoblot for the presence of coimmuno-
precipitated BZLF1 protein using the BZ.1 antibody. BZLF1 is coimmunopre-
cipitated with the BMRF1 antibody, but not the Rb antibody, from B95-8 cell
extracts. The BMRF1 antibody does not immunoprecipitate BZLF1 transfected
into the EBV-negative HeLa cell line, indicating that this antibody does not
cross-react with BZLF1.
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FIG. 5. The BMRF1 gene product modulates BZLF1 transactivator function. (A) The expression level of transfected BZLF1 in the presence and absence of the
cotransfected BMRF1 gene product was determined by immunoblot analysis. Cotransfection of BMRF1 does not significantly alter the expression of transfected BZLF1
protein or vice versa. (B) Five micrograms of the BHRF1-CAT reporter construct (containing the BHRF1 early EBV promoter) was transfected into HeLa cells with
either 5 mg of pSG5 vector DNA–5 mg of pHD1013 vector DNA (Vector), 5 mg of the BMRF1 expression vector–5 mg of the pHD1013 vector (BMRF1), 5 mg of pSG5
vector DNA–5 mg of the BZLF1 expression vector (Z), or 5 mg of the BMRF1 expression vector–5 mg of the BZLF1 expression vector (Z 1 BMRF1). The percent
acetylation of 14C-labelled chloramphenicol in each condition was measured as previously described (28). Results are expressed as the amount of CAT activity induced
by the BMRF1 and BZLF1 expression vectors relative to the amount induced by the vector alone. (C) Five micrograms of the BMRF1-CAT reporter construct
(containing the early EBV BMRF1 promoter) was transfected into HeLa cells under the same conditions described for the BHRF1-CAT construct. BZLF1-induced
activation of the BMRF1 promoter was significantly inhibited by the presence of the BMRF1 gene product (P, 0.05, using a two-tailed t test with 3 degrees of freedom).
(D) Five micrograms of the BHLF1-CAT reporter construct, containing the early EBV BHLF1 promoter, was transfected into HeLa cells under the same conditions
described for BMRF1-CAT. The fold activation induced by each transactivator (compared with the effect of vector DNA alone) is shown. Note that the scale for the
Z and Z 1 BMRF1 conditions is different from that for the Vector and BMRF1 conditions. The activation of the BHLF1 promoter was significantly greater using the
combination of the BZLF1 and BMRF1 gene products versus that for BZLF1 alone (P , 0.05 in a two-tailed t-test with 4 degrees of freedom).
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binding function but does not require direct interaction be-
tween the BZLF1 and BMRF1 proteins.
The BZLF1D200 mutant is impaired in its ability to induce
lytic replication of the latent EBV genome. The previous re-
sults suggest that direct, as well as indirect, interactions be-
tween the BZLF1 and BMRF1 gene products can modulate
the ability of BZLF1 to activate various EBV early promoters.
However, since the BZLF1 and BMRF1 proteins have repli-
cative as well as transcriptional functions, the BZLF1-BMRF1
interaction might also be important in modulating replication.
To further examine this point, we compared the ability of
wild-type BZLF1 with that of mutant BZLF1D200 to mediate
lytic replication in EBV-infected D98/HE-R-1 cells.
Two different types of replication assays were used. The first
assay quantitates the ability of transfected BZLF1 to induce
replication of a cotransfected plasmid containing the EBV
oriLyt element (21, 55). The second assay (the terminus assay)
(51, 53) examines the ability of transfected BZLF1 to induce
lytic replication of the endogenous genome. The terminus as-
say distinguishes between the latent virus genome, which con-
tains only fused (episomal) termini, and the lytically replicated
genome, which has both an increased number of fused termini
(due to concatameric replication intermediates) (53) and un-
fused termini (due to the replicated linear form).
Although the BZLF1 gene product can activate expression
of reporter gene constructs driven by the BZLF1 promoter in
transient assays (23), we and others have found that overex-
pression of the BZLF1 gene product in latently infected cells
does not significantly activate expression of the endogenous
viral BZLF1 promoter (40, 72). Hence, essentially all of the
BZLF1 protein in BZLF1-transfected D98/HE-R-1 cells is de-
rived from the expression vector (rather than the endogenous
genome), allowing us to compare the replication efficiencies of
the wild-type and mutant proteins. The relative amounts of
transfected BZLF1 RNA and BZLF1 RNA derived from the
endogenous D98/HE-R-1 genome are shown in Fig. 8A. An
RNase protection assay demonstrated that less than 1% of the
total BZLF1 RNA is derived from the endogenous genome.
Since it is likely that defects in BZLF1 transcription function
could inhibit its replication function, we first demonstrated
that the wild-type and mutant BZLF1 proteins have similar
transcriptional function in D98/HE-R-1 cells (a latently in-
fected, EBV-positive epithelial cell line). As shown in Fig. 8A,
the wild-type and mutant BZLF1 proteins activated the imme-
diate-early BZLF1 and BRLF1 promoters in the endogenous
D98/HE-R-1 viral genome with similar efficiencies. Likewise,
the wild-type and mutant BZLF1 proteins produced similar
activation of two early EBV promoters (BHRF1 and BHLF1)
in D98/HE-R-1 cells in transient reporter gene assays (Fig.
8B). The BMRF1 promoter construct was more efficiently ac-
tivated by the mutant BZLF1D200 protein than by wild-type
BZLF1 in D98/HE-R-1 cells, presumably because the ability of
the wild-type, but not mutant, BZLF1 protein to activate the
BMRF1 promoter is inhibited in the presence of BMRF1 pro-
tein derived from the endogenous D98/HE-R-1 viral genome
(Fig. 7A). Transfection of the BZLF1D200 protein consistently
induced as much (or more) BMRF1 expression from the en-
dogenous D98/HE-R-1 genome (assessed by Western blot
analysis) as did the wild-type BZLF1 protein (Fig. 8C). Thus,
in a variety of different transcriptional assays, the mutant
BZLF1 functioned as well as (or better than) the wild-type
BZLF1 in D98/HE-R-1 cells.
The results of the replication experiments are shown in Fig.
8D and E. In plasmid-based replication assays, the wild-type
and mutant BZLF1 proteins induced similar levels of replica-
tion (Fig. 8D). However, in the terminus assay (which mea-
sures replication from the endogenous viral genome), the
amount of EBV replication induced by the BZLF1D200 mu-
tant was consistently less than that induced by wild-type
BZLF1, in spite of the previous finding that early gene expres-
sion induced from the endogenous genome was similar (Fig.
8E). In control experiments, the amount of the cellular actin
gene was found to be similar in each condition.
DISCUSSION
In this report we have demonstrated that the EBV replica-
tive protein BMRF1 functions as a specific activator of an
essential oriLyt promoter (BHLF1) in addition to its previ-
ously defined role as the viral polymerase processivity factor.
We have also shown that the BMRF1 protein can physically
and functionally interact with the EBV BZLF1 transactivator
protein. Our results suggest that the BZLF1 and BMRF1 pro-
teins each have transcriptional, as well as replicative, roles
during lytic EBV infection. The direct and indirect interactions
between the BZLF1 and BMRF1 proteins may thus modulate
both viral transcription and viral replication.
The BZLF1 gene product plays a unique role in EBV biol-
ogy in that it is the only viral protein currently known to initiate
the switch from latent to lytic infection. BZLF1 transactivator
function is required for expression of the early viral proteins
(BALF5, BMRF1, BALF2, BSLF1, BBLF4, and BBLF2/3)
directly involved in mediating oriLyt replication. Transcription
factors have been shown to play an important, but auxiliary,
role in mediating the replication of other viruses (16, 30, 41, 46,
68, 69). It has been suggested that BZLF1 may play a role in
replication apart from its transcriptional function (21, 54).
FIG. 6. The BMRF1 gene product decreases BZLF1 binding to ZREs. HeLa
cells were transfected with either vector DNA (lane 2), BZLF1 alone (lanes 3 to
5), BZLF1 and BMRF1 (lane 6), or BMRF1 alone (lane 7). Cell extracts were
prepared and tested for their ability to bind to a labelled oligonucleotide probe
containing two ZRE sites. The specific BZLF1 complex is indicated by the arrow
Z. The BMRF1 gene product reduced binding of BZLF1 to the synthetic oligo-
nucleotide probe.
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oriLyt contains numerous BZLF1 binding sites, and BZLF1
binding to these sites appears to be required for replication in
a way that is at least partially separable from the BZLF1
transcriptional effect (54). Similar to the proposed functions of
other origin-binding proteins (2, 15, 17, 18, 25, 29, 46, 48, 58,
70), BZLF1 binding to oriLyt could potentially be required for
stabilization of the replication complex and/or opening up the
chromatin structure around the replication initiation site.
The BMRF1 protein is known to be a component of the
active viral polymerase (10, 34, 38–40, 42, 62–64) but has not
previously been shown to activate lytic EBV transcription.
Oguro et al. (47) reported that the BMRF1 gene product can
activate expression of the early SV40 promoter. We have like-
wise found that the BMRF1 gene product activates the SV40
early promoter (data not shown), although the magnitude of
this effect is less than what we observe with the BHLF1 pro-
moter. However, two other groups (6, 67) have failed to find
that BMRF1 is a transcriptional activator. Most recently, Chen
et al. created a fusion protein containing the yeast GAL4 DNA
binding domain linked to either the carboxy-terminal 100
amino acids of BMRF1 (a region rich in prolines) or the entire
BMRF1 protein (6). These GAL4-BMRF1 fusion proteins did
not activate transcription of a reporter gene construct contain-
ing GAL4 DNA binding motifs (6). It is possible that these
negative results reflect improper folding of the GAL4-BMRF1
fusion proteins. Alternatively, the BMRF1 protein, rather than
containing a conventional transactivator domain, may mediate
its effects indirectly by regulating the activity of one or more
cellular transcription factors. Regardless of the mechanism,
our finding that the BMRF1 gene product activates oriLyt
transcription was unexpected and suggests that the role of
BMRF1 in oriLyt replication is much more complex than pre-
viously appreciated.
The physical interaction between BMRF1 and BZLF1 re-
quires the first 45 amino acids of BMRF1 and the bZip domain
(specifically amino acid 200) of BZLF1. The amino-terminal
45 amino acids in BMRF1 do not contain a bZip dimerization
domain or other known sequence motifs and are not required
for DNA binding activity or polymerase processivity function
(39). Although defining the precise BMRF1 sequences re-
quired for interaction with BZLF1 will require further study, it
should be possible to construct BMRF1 mutants which retain
polymerase processivity function but which have lost the ability
to interact directly with BZLF1.
We have shown here that the BMRF1 and BZLF1 gene
products directly and indirectly interact to regulate EBV tran-
scription and possibly EBV replication as well. In regard to
transcriptional effects, our data suggest that one result of the
direct interaction between the BZLF1 and BMRF1 proteins is
negative regulation of the BMRF1 promoter. BZLF1-depen-
dent transcription of the BMRF1 promoter is clearly reduced
in the presence of the BMRF1 protein, suggesting a mecha-
FIG. 7. Direct interaction between the BMRF1 and BZLF1 proteins corre-
lates with the inhibition of BMRF1 transcription but not with the activation of
BHLF1 transcription. (A) The BMRF1-CAT reporter plasmid was cotransfected
into HeLa cells with either vector DNA, the BMRF1 expression plasmid alone,
the wild-type BZLF1 expression vector alone (Zwt), the wild-type BZLF1 vector
plus the BMRF1 expression plasmid (Z 1 BMRF1), the BZLF1D200 expression
plasmid alone (ZD200), or BZLF1D200 plus BMRF1. (B) The BHLF1-CAT
construct was transfected into HeLa cells with either vector DNA, the BMRF1
expression vector, the mutant BZLF1D200 expression vector (ZD200), the mu-
tant BZLF1D200 expression vector and the BMRF1 expression vector, the mu-
tant Z311 expression vector (mutated at amino acid 185), or the mutant Z311
expression vector and the BMRF1 expression vector. Similar results were ob-
tained in a repeat experiment. (C) HeLa cells transfected with either the wild-
type or mutant BZLF1 expression vectors were analyzed by immunoblot analysis
(48 h after transfection), using the BZLF1-specific antibody BZ.1.
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nism whereby the BMRF1 gene product can negatively regu-
late its own expression. In contrast, a BZLF1 protein mutated
at residue 200 (which is unable to directly interact with the
BMRF1 protein) activated BMRF1 transcription equally well
in the presence or absence of the BMRF1 protein. Thus, the
ability of BMRF1 to inhibit its own transcription seems to
require its direct interaction with BZLF1.
Our DNA binding studies suggest that the BZLF1-BMRF1
complex may be incapable of binding to ZRE sites, potentially
providing a mechanism by which expression of the BMRF1
gene product inhibits BMRF1 promoter activity. Nevertheless,
BZLF1-induced transcription of at least two other early EBV
promoters (BHLF1 and BHRF1) continued to be active (or in
the case of the BHLF1 promoter, actually increased) in the
presence of the BMRF1 gene product, even though BZLF1
binding to these promoters was also found to be decreased. It
is possible that the BMRF1-induced reduction in BZLF1 bind-
ing activity only has functional significance in those promoters
(such as the BMRF1 promoter) which have relatively few up-
stream ZREs. We have previously shown that deletion of ei-
ther of the two upstream ZRE sites in the BMRF1 promoter
drastically reduces BZLF1-induced transcription (50), suggest-
ing that both ZRE sites need to be simultaneously bound by
BZLF1 for activation of this promoter. In contrast, promoters
containing a larger number of upstream ZREs may be active
when only a portion of the ZRE sites are occupied by BZLF1.
The divergent oriLyt promoters (BHRF1 and BHLF1) share
seven ZREs (55).
In this study, we have demonstrated that BMRF1, like
BZLF1, has a dual role as both a transcriptional activator and
an essential replicative protein. The linkage between the tran-
scriptional activation of oriLyt and the assembly of the EBV
replication machinery over oriLyt is complex and probably
FIG. 8. Replication induced by the wild-type versus mutant BZLF1 proteins.
(A) Total cellular RNA was isolated from Akata Burkitt cells (either untreated
or treated with 30 ng of TPA per ml for 4 h) and from D98/HE-R-1 cells 1 day
after transfection with either vector DNA, wild-type BZLF1 expression vector
(Zwt), or the BZLF1D200 expression vector. The RNA was hybridized to a
single-stranded 32P-labelled riboprobe (spanning the BZLF1 mRNA start site),
digested with RNase (Promega RNase protection kit), denatured, and run on a
6% sequencing gel. Hybridization of this probe to Zp (the promoter driving
BZLF1 transcription)- and Rp (the promoter driving BRLF1 transcription)-
derived messages results in protected fragments of 115 and 148 bp, respectively.
The transfected BZLF1 vector yields an 80-bp protected fragment. (B) Five
micrograms of the BMRF1-CAT, BHRF1-CAT, or BHLF1-CAT plasmid was
transfected into D98/HE-R-1 cells with either 5 mg of pHD1013 vector DNA, 5
mg of the wild-type BZLF1 expression vector, or 5 mg of the mutant BZLF1D200
expression vector. The fold activation induced by each BZLF1 construct is
shown. (C) D98/HE-R-1 cells were transfected with 5 mg of wild-type BZLF1,
BZLF1D200, or BZLF1D225. The level of BMRF1 expression induced from the
endogenous genome by each BZLF1 vector was measured by immunoblot. (D)
D98/HE-R-1 cells were transfected with 5 mg of the oriLytDKpn plasmid–5 mg of
pHD1013 vector DNA, 5 mg of the oriLytDKpn plasmid–5 mg of the wild-type
BZLF1 expression vector, or 5 mg of the oriLytDKpn plasmid–5 mg of the
BZLF1D200 expression vector. DNA was analyzed 3 days after transfection by
cutting with the restriction enzymes BamHI and DpnI and probing with a 32P-
labelled riboprobe spanning the EBV oriLyt sequences. The positions of the
DpnI-cut (Input) and DpnI-resistant (replicated [Rep]) oriLytDKpnI plasmid are
shown. The wild-type and mutant BZLF1 proteins had similar replication effi-
ciencies in two separate experiments with this plasmid-based replication assay.
(E) D98/HE-R-1 cells were transfected with 5 mg of pHD1013 vector DNA, 5 mg
of the wild-type BZLF1 expression vector, or 5 mg of the BZLF1D200 expression
vector. DNA was analyzed 3 days after transfection by cutting with the restriction
enzyme BamHI and probing with a 32P-labelled riboprobe spanning the EBV
sequences in the 1.9-kb XhoI (termini) fragment. As previously described (51,
53), lytic replication results in increased amounts of fused viral termini (resulting
from the replicated concatameric intermediates) as well as unfused termini (seen
only in the replicated linear form). A representative experiment is shown on the
right. The blot was reprobed with a 32P-labelled probe species for the cellular
actin gene, which confirmed that equal amounts of DNA were present in each
condition. Quantitation of the results (from three experiments) is shown on the left.
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differs greatly from the activation of alphaherpesvirus replica-
tion origins. An unresolved issue is whether the BZLF1-
BMRF1 interaction plays a role in oriLyt replication apart
from its role in transcriptional regulation. Mutational analysis
of the BZLF1 and BMRF1 genes within the context of the
intact viral genome should help to clarify this issue.
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